Loading...Loading...Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of$0.16.Fourth-quarter sales totaled $70.98 million, beating the analyst consensus of$70.89 million, according to data from Benzinga Pro.Pro forma net sales rose 1.9% to $71.1 million. Med Tech segment net sales were$29.3 million, up 11.3% year over year.Growth was driven by Auryon sales of $13.0 million, which increased 12.0%, NanoKnife disposable sales ...